<DOC>
	<DOCNO>NCT00443768</DOCNO>
	<brief_summary>To identify patient within community take anti-parkinson medication diagnosis Parkinson 's disease incorrect supervise clinically monitor withdrawal anti-parkinson medication patient group</brief_summary>
	<brief_title>Medication Review Patients Anti-parkinson Therapy</brief_title>
	<detailed_description>Step 1 - Practice base pharmacist medical review use database search following : - Anti-parkinson drug therapy ( exclude anticholinergic monotherapy ) . - Disease cod identify Parkinson 's disease parkinsonism , exclude diagnose anti-parkinson therapy may use , although expect small number ( pituitary tumour , restless leg syndrome ) - To identify duration parkinsonism date entry disease code . - Pharmacy re-fill data identify intermittent usage treatment indicator unlikely patient idiopathic dopa responsive parkinsonism . - To identify patient monotherapy anti-parkinson therapy e.g . Selegiline prolong duration likely suggest alternative diagnosis . - To record drug dosage time , e.g . annual basis , identify whether patient fit expect rate change degenerative parkinsonism increase combination drug high dos use time . Step 2 - Review case record : · Parkinson 's disease nurse specialist medical review case record identify additional clinical feature condition assist identify case appear likely anti-parkinson drug treatment help patient 's condition . Step 3 - Specialist out-patient review follow-up : · Invitation patient attend combine neurology/medicine elderly movement disorder clinic service score diagnostic clinical criterion would undertake , appropriate taper anti-parkinson therapy gradually continue specialist observation .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Patients antiparkinson medication : Have monotherapy prolonged period , Use antiparkinson medication intermittently , Do expect change medication time keep degenerative Parkinson 's disease . Patients antiparkinson medication reason Parkinson 's disease . Patients significant comorbidity ( end stage liver , cardiac renal disease ) .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Medication</keyword>
	<keyword>Diagnosis</keyword>
	<keyword>Community</keyword>
</DOC>